Answers are grounded in this paper and cite their sources.
Binding of FOXP3 to the PD-L1 promoter and FOXP3-dependent IFNγ-mediated gene expression. A, Schematic of the PD-L1 promoter upstream of the transcription start site in HT1376 cells. B, ChIP PCR of the putative FOXP3-binding sites of the PD-L1 promoter. Input chromatin, beads only, isotype Ab and HT1376 cells untreated or treated with IFNγ as indicated. Sizes in kb as indicated. C, Activation of a PD-L1 reporter by overexpression of FOXP3Δ3 and FOXP3 by a luciferase reporter assay. All putative FOXP3-binding sites were individually mutated as shown. Activation of a NK-κB reporter by TRAF6 overexpression was used as a positive control. Control plasmid activation of each distinct promoter was set as baseline. Fold activation is shown and represents the mean of triplicates, P values indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. The results are representative of two independent experiments. D, GSEA of RNA-seq from clonal HT1376 CT and HT1376 FOXP3 KO lines performed in triplicates. FDRs and P values are shown in Supplementary Table S1. E, Derivation of FOXP3-dependent IFNγ-mediated genes in HT1376 CT and HT1376 FOXP3 KO lines without and with IFNγ stimulation. RNA-seq as the mean of triplicate samples. FDR and P values shown in Supplementary Tables S2 and S3. F, Heat map analysis of FOXP3-dependent IFNγ-mediated gene expression from HT1376 CT and HT1376 FOXP3 KO lines without and with IFNγ stimulation by Z score. Z scores are shown in Supplementary Fig. S4 and Supplementary Table S4. Normalized gene expression data are shown in Supplementary Table S5. G, Subset of heat maps highlighting genes important in immune regulation and EMT.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: